SUMMIT, NEW JERSEY, August 7, 2013 — Merck Animal Health (known as MSD Animal Health outside the USA and Canada) announced today the company will participate in this year’s AQUA NOR 2013 in Trondheim, Norway, 13-16 August 2013. The exhibition draws international participation of key industry and academic leaders to discuss the latest advancements in salmon and cold water aquaculture health management. Expected to be the largest AQUA NOR event ever, attendees can visit the Merck Animal Health booth in Hall D at stand number D-342.
“We are pleased to participate in this year’s AQUA NOR. This is a significant exhibition for our company as the worldwide demand for safe and plentiful fish continues to grow at a significant rate,” said Johan Kvalheim, recently appointed General Manager, Norway. “AQUA NOR 2013 gives us the opportunity to share our commitment to the salmon trade and larger aquaculture industry with some of the biggest thought leaders from around the world.”
In addition to an information booth at the conference, the company will host a seminar titled ‘Team Aquatic’ on Wednesday 14th August. During this invite-only seminar, fish health personnel will learn about the latest research in sea lice, pancreas disease and cold water Vibriosis vaccination. Attendees interested in participating in the seminar should contact their local Merck Animal Health representative to inquire about an invitation.
“Norway contributed more than 1 million tonnes of salmon to the market in 2012 with that number expected to rise in 2013,” says Kvalheim. “Keeping those fish free of the harmful diseases that can easily infiltrate the farms is important. We are happy to provide important data that will help farmers maintain the health of their stocks.”
Johan Kvalheim, who joined the company in April of this year from The Norweigan Seafood Council, will be available at the company booth throughout the event to discuss the latest trends and research in fish health with attendees.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).